Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

GPhC council members voted to give themselves 20% pay rise in May meeting

Members of the General Pharmaceutical Council (GPhC) will be paid £2,500 more each per year to fulfil their duties, after voting in favour of this plan at a meeting earlier this month.

GPhC council member remuneration has remained fixed at £12,500 per annum since April 2018, making this their first pay rise since then, a GPhC spokesperson told C+D today (May 25).

Members are set to receive £15,000 per annum in 2022/2023 for their duties, amounting to a 20% pay rise, following a council meeting earlier this month (May 12).

The GPhC “will backdate the increase to April 1”, the spokesperson said.

The vote follows a recommendation from the GPhC’s workforce committee, which it made following a report conducted by reward and employee experience consultancy firm QCG

 

GPhC’s remuneration “lower” than other regulators

 

The GPhC’s workforce committee annually reviews how much council members are paid and any recommendations for remuneration changes are introduced on April 1 every year.

Although the regulator “took the decision not to recommend an increase in member remuneration for 2021”, it was decided that “a broader review should be conducted” for 2022.

QCG benchmarked GPhC council members’ pay against equivalent roles at other organisations including the General Medical Council, the Nursing and Midwifery Council and the General Dental Council, whose members receive £18,000, £14,724 and £15,000 per annum respectively, according to the council papers.

“The findings of [the QCG’s] analysis showed that GPhC remuneration was lower than the median figure for the wider pool of regulators,” the spokesperson said.

 

Read more: GPhC appoints Gisela Abbam as new chair

 

It is “important that [the rise in remuneration] is recognised as a re-basing increase rather than an accumulation of incremental increases for the period from 2019”, the regulator noted in in its council papers.

The GPhC chair’s remuneration, however, which was last reviewed in 2021, “appears sufficient at £60,000”, the regulator determined.

 

Additional responsibilities

 

While the regulator’s “direct comparators” did not have “additional responsibility for premises or businesses”, the QCG’s report noted the GPhC supervises 13,977 pharmacies, which seems to have further tipped the balance in favour of recommending higher remuneration for council members.

“The pandemic has provided a clear example of how pharmacy is developing as a profession and the increased clinical responsibility placed on pharmacy professionals is likely to continue and to develop further,” the regulator wrote in its papers.

“This increases the profile of both the profession and the regulator, as well as the attendant risks,” it said in explanation of the proposal.

The higher remuneration will be “appropriate for members’ responsibilities”, the regulator wrote, and ensure that the GPhC can “continue to attract the calibre of members required”.

 

Related Content

Topics

         
Registrant member of the Assurance and Appointments Committee 
Nationwide
£ Renumeration

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD136145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel